Study identifier:D5880C00003
ClinicalTrials.gov identifier:NCT02189252
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women with a History of Pancreatitis
severe hypertriglyceridemia
Phase 1
No
Epanova, Lovaza
All
30
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 May 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: E4:L4 Crossover Sequence | - |
Active Comparator: L4:E4 Crossover Sequence | - |
Active Comparator: E2:L4 Crossover Sequence | - |
Active Comparator: L4:E2 Crossover Sequence | - |